Our new sister publication, Cannabis Science and Technology (CST), launched in March 2018. In alliance with the Cannabis Science Conference, this new professional journal and website will focus on educating the legal cannabis industry about the science and technology of analytical testing and quality control, including topics such as
· Sample preparation techniques for analytical testing
· Development of analytical methods for potency testing
· Identifying contaminants such as pesticides, residual solvents, heavy metals, and mycotoxins
· Quality control for cannabis, extraction, and processing
· Laboratory best practices and certification
· Testing standardization
· Regulations related to quality control
The first issue features content ranging from quality assurance, laboratory accreditation, analytical tools to analyze edibles, metals analysis, extraction processes, and more. To read the full issue, please visit www.cannabissciencetech.com/journal/cannabis-science-and-technology-vol-1-no-1 or download the digital edition.
If you would like to submit an article to Cannabis Science and Technology, contact Meg L’Heureux, Editor-in-Chief at Meg.Lheureux@ubm.com.
For subscription information, please visit http://www.cannabissciencetech.com/subscribe
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.